Wall Street equity research analysts tracking Agenus establish varying price targets that reflect the binary, high-volatility nature of clinical-stage biotechnology stocks. While conservative models account for ongoing cash burn and regulatory hurdles, optimistic consensus targets project substantial upside potential over medium-to-long-term horizons, with analytical forecasts and target ranges scaling dynamically based on clinical trial readouts, partnership announcements, and FDA regulatory updates.